Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII.
Three patients with mild haemophilia A who developed high-titre antibodies against factor VIII at high age are reported. These patients had only a limited number of exposure days of FVIII concentrates in the past. The patients had to undergo surgery or presented with recurrent bleeding episodes. Treatment with recombinant FVIIa (rFVIIa) was effective and safe. Despite the high age and the presence of coronary heart disease in one of the patients, no adverse events or thrombotic complications occurred. These cases illustrate that the physician should always be alert on the development of inhibitors, also in elderly patients with mild haemophilia, in whom FVIII inhibitors had never been detectable before and that treatment with rFVIIa was effective and well-tolerated.
Leebeek
F W G
FW
Department of Hematology, Haemophilia Treatment Center, Erasmus University Medical Center, Rotterdam, The Netherlands. f.leebeek@erasmusmc.nl
Kappers-Klunne
M C
MC
Jie
K S G
KS
D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000378:metabolism*; D005167:Factor VII / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology*; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*
D000906:Antibodies; D011994:Recombinant Proteins; D005167:Factor VII; D005169:Factor VIII; C103587:recombinant FVIIa; D015942:Factor VIIa